Letter: Increased pulmonary toxicity results from a 1-day versus 2-day schedule of administration of high-dose melphalan  by Williams, Lori et al.
334
Melphalan at doses of 140-200 mg/m2 is a standard
preparative regimen for autologous hematopoietic stem cell
transplantation in multiple myeloma (MM) patients [1]. In a
study by Akasheh et al. [2], 4 patients (7%) treated with high-
dose melphalan (HDM) 200 mg/m2 developed acute onset of
pulmonary symptoms that required hospitalization. All
4 patients were hypoxic and hypercapneic, with chest x-rays
showing bilateral diffuse interstitial inﬁltrates without pul-
monary effusions or cardiomegaly [2]. Badros et al. [1]
recently reported excessive pulmonary toxicity and mortality
(16%) among MM patients ≥70 years old receiving HDM
200 mg/m2 compared to patients receiving HDM 140 mg/m2.
Although patients receiving HDM 200 mg/m2 had signiﬁ-
cantly longer complete response (CR) duration, the likeli-
hood of achieving a CR and the overall and event-free sur-
vival were not signiﬁcantly different for the 2 groups [1]. 
From December 1999 through March 2001, courses of
HDM 200 mg/m2 given intravenously with autologous
peripheral blood progenitor cell support were administered
according to an institutional review board–approved proto-
col to 147 patients at 21 transplantation centers throughout
the United States. After reconstitution according to manufac-
turer’s recommendations, all doses of HDM were added to
0.9% NaCl at a concentration no greater than 0.45 mg/mL.
Infusion of the drug was completed within 1 hour of recon-
stitution. One hundred twenty consecutive patients received
HDM 200 mg/m2 in 2 evenly divided doses over 2 days
(MEL100×2). The protocol was then amended to administer
the dose of HDM 200 mg/m2 (MEL200) on a single day for
improved patient convenience after it was reported by Tricot
(University of Arkansas, personal communication) that it was
well tolerated. Twenty-seven consecutive patients then
received MEL200. Because of increased toxicity, especially
pulmonary toxicity, noted in these 27 patients, administra-
tion of MEL200 was stopped. Except for group size and
method of administration, the 2 patient groups were equiva-
lent. There was no signiﬁcant difference in age, sex, or race
distribution between the groups, and all patients met the
same protocol eligibility criteria for disease stage, prior ther-
apy, and end-organ function. 
The serious adverse events experienced by the 2 groups
of patients, the relative risk with confidence intervals of
developing toxicity with MEL200, and the 2-tailed proba-
bility of a difference in toxicities between the 2 groups are
summarized in the Table.
The mean number of days in the specialty care unit was
10 days (range, 8-13 days) for the MEL200 group and 7 days
(range, 3-11 days) for the MEL100×2 groups. Three of the
4 pulmonary toxicities in the MEL200 group were nonin-
fectious interstitial pneumonitis. Four of the 5 pulmonary
toxicities in the MEL100×2 groups were infectious.
HDM can cause pulmonary toxicity. This report and
others [1,2] have documented that single doses of HDM >
140 mg/m2 are associated with increased incidence of pul-
monary toxicity. With the number of transplantations for
MM increasing and many of these procedures being per-
formed in older patients, it would seem prudent to avoid
doses of HDM > 140 mg/m2 given on a single day. In addi-
tion, predictors of pulmonary toxicity from HDM should be
investigated more fully.
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Adverse Events and MEL200 Toxicity
1-Day Dose 2-Day Dose RR (95% CI)* P†
Total no. of transplantations 27 120
Transplantations with serious adverse events 9 (33.3%) 20 (16.7%) 2.0 (1.03-3.90) .050
Transplantations with grade III-IV toxicity 19 (70.3%) 46 (38.3%) 1.8 (1.3-2.6) .003
Transplantations with grade III-IV pulmonary toxicity 4 (14.8%) 5 (4.2%) 3.6 (1.02-12.4) .038
Transplantations with pulmonary toxicity requiring specialty care unit admissions 3 (11.1%) 2 (1.7%) 6.7 (1.2-38.0) .015
Transplantations with pulmonary toxicity requiring mechanical ventilation 2 (7.4%) 0 (0%) 21.6 (1.07-438) .003
*Relative risk (RR) with conﬁdence intervals (CI) of developing toxicity with MEL200. 
†Two-tailed probability of a difference in toxicities between the 2 groups.
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